Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR phase 3 trial of lenvatinib combinations versus sunitinib in first-line advanced renal cell carcinoma
MOH_2017-05-14_000343Phase 3Not yet recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2017
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenvatinib, everolimus, pembrolizumab and sunitinib in renal cell carcinoma (RCC) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-free survival. Planned start Apr 2017; status: not yet recruiting.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2017-05-14_000343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-14_000343.